Background: Immunomodulators (IMMs), including thiopurines (TPs) and methotrexate (MTX), are commonly used in the treatment of inflammatory bowel disease (IBD). Key Messages: In ulcerative colitis (UC), TPs have modest steroid-sparing effects and established efficacy in maintenance of remission. The role of MTX in UC is unclear but current evidence suggests no benefit over placebo. In Crohn's disease (CD), MTX is not effective for induction but has a modest steroid-sparing effect and is superior to placebo in maintenance of remission in responders. The addition of MTX to infliximab reduces immunogenicity and boosts infliximab levels but does not improve outcomes in active CD. TPs are not effective for induction of remission in CD but have proven steroid-sparing effects and modest efficacy in maintenance of remission and prevention of postoperative recurrence. Although effective in pediatric CD, recent evidence has questioned the benefit of early TPs in newly diagnosed adult CD. The addition of TPs to infliximab reduces immunogenicity and inflammatory markers, leads to higher infliximab levels and improves outcomes in patients with early disease. However, the benefit of continued TP therapy in this setting is unclear and should be weighed against possible side effects including an increased risk of opportunistic infections, lymphoma and non-melanoma skin cancer. Conclusions: IMMs are an important therapeutic option in IBD particularly in non-severe steroid-dependent disease and for maintenance of remission. Combination with anti-TNF agents is an important emerging option as part of a treat-to-target strategy but further research regarding patient selection, long-term use and de-escalation options is needed.

Keywords:
Thiopurines, Azathioprine, Methotrexate, Crohn’s disease , Ulcerative colitis
1.
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF: Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-1338.
2.
Rosenberg JL, Levin B, Wall AJ, Kirsner JB: A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975;20:721-726.
3.
Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
4.
Hindorf U, Andersson P: How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease? Scand J Gastroenterol 2011;46:1215-1221.
5.
Chande N, Tsoulis DJ, MacDonald JK: Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2013;4:CD000545.
6.
Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB: American gastroenterological association institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013;145:1464-1478.e1-e5.
7.
Prefontaine E, Macdonald JK, Sutherland LR: Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010;6:CD000545.
8.
Markowitz J, Grancher K, Kohn N, Lesser M, Daum F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
9.
Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID): Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 2013;145:758-765.e2; quiz e14-e15.
10.
Panes J, Lopez-Sanroman A, Bermejo F, Garcia-Sanchez V, Esteve M, Torres Y, Domenech E, Piqueras M, Gomez-Garcia M, Gutierrez A, Taxonera C, Sans M; AZTEC Study Group: Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145:766-774.e1.
11.
Gordon M, Taylor K, Akobeng AK, Thomas AG: Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2014;8:CD010233.
12.
Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF: Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009;104:2089-2096.
13.
Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, Frigo AC, Fazio V, Marabotto E, Savarino V: Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol 2013;108:1731-1742.
14.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV: Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015;385:1406-1417.
15.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits S, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV: Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther 2015;42:867-879.
16.
Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F: Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-137.
17.
Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53.
18.
Sood R, Ansari S, Clark T, Hamlin PJ, Ford AC: Long-term efficacy and safety of azathioprine in ulcerative colitis. J Crohns Colitis 2015;9:191-197.
19.
Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9:CD000478.
20.
Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group: Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015;148:1035-1058.e3.
21.
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives: Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-1915.
22.
Walch A, Meshkat M, Vogelsang H, Novacek G, Dejaco C, Angelberger S, Mikulits A, Miehsler W, Gangl A, Reinisch W: Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine a is determined by previous exposure to thiopurines. J Crohns Colitis 2010;4:398-404.
23.
Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S: Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:674-688.
24.
Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S: First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-351.
25.
Nanda KS, Cheifetz AS, Moss AC: Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-47; quiz 48.
26.
Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ: Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther 2015;41:734-746.
27.
Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J: Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-1368.
28.
van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, Veenendaal RA, van der Meulen-de Jong AE: Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis 2014;20:2292-2298.
29.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-1395.
30.
Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P: Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009;15:375-382.
31.
Rogler G: Top-down or step-up treatment in Crohn's disease? Dig Dis 2013;31:83-90.
32.
Danese S, Colombel JF, Reinisch W, Rutgeerts PJ: Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-869.
33.
Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM, Chen L, Xie F, Curtis JR, Lewis JD: Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 2015;13:1293-1301.e5; quiz e70-e72.
34.
Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P: Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.
35.
Lee YY, Gangireddy V, Khurana S, Rao SS: Are we ready for combination therapy in moderate-to-severe ulcerative colitis? Gastroenterology 2014;147:544.
36.
Kamath N, Kamath A, Pai CG: Infliximab for moderate to severe ulcerative colitis: the jury isn't in yet. Gastroenterology 2014;147:544-545.
37.
Egan LJ, Sandborn WJ: Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996;71:69-80.
38.
Swaminath A, Taunk R, Lawlor G: Use of methotrexate in inflammatory bowel disease in 2014: a user's guide. World J Gastrointest Pharmacol Ther 2014;5:113-121.
39.
Haisma SM, Lijftogt T, Kindermann A, Damen G, de Ridder L, Escher JC, Mearin ML, de Meij T, Hendriks D, George E, Hummel T, Norbruis O, van Rheenen P: Methotrexate for maintaining remission in paediatric Crohn's patients with prior failure or intolerance to thiopurines: a multicenter cohort study. J Crohns Colitis 2015;9:305-311.
40.
Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, et al: Methotrexate for the treatment of Crohn's disease. The North American Crohn's study group investigators. N Engl J Med 1995;332:292-297.
41.
Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's study group investigators. N Engl J Med 2000;342:1627-1632.
42.
McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG: Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2014;8:CD003459.
43.
Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N: Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2014;8:CD006884.
44.
Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A, Fedorak RN, Paré P, Bitton A, Saibil F, Anderson F, Donner A, Wong CJ, Zou G, Vandervoort MK, Hopkins M, Greenberg GR: Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681-688.e1.
45.
Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Bardan E, Villa Y, Gilat T: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-1421.
46.
Chande N, Wang Y, MacDonald JK, McDonald JW: Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014;8:CD006618.
47.
Wang Y, MacDonald JK, Vandermeer B, Griffiths AM, El-Matary W: Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;8:CD007560.
48.
Carbonnel F, Colombel JF, Filippi J, Katsanos K, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Dupas JL, Roblin X, Bouhnik Y, Reinisch W, Färkkilä MA, Brixi H, Seksik P, Malamut G, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti PF, Sarter H, Laharie D: 745 methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial. Gastroenterology 2015;148:S140.
49.
Carbonnel F, Colombel JF, Filippi J, Katsanos K, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Dupas JL, Roblin X, Bouhnik Y, Reinisch W, Farkkila M, Brixi H, Seksik P, Malamut G, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D: Methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial. J Crohns Colitis 2015;9:S14-S15.
50.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
51.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
52.
Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F: Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015;372:1104-1113.
53.
Olesen MT, Ballarín-González B, Howard KA: The application of RNAI-based treatments for inflammatory bowel disease. Drug Deliv Transl Res 2014;4:4-18.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.